A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): Analysis of safety and activity of the FALCON trial
| Autor: | Jeffrey D. Neidhart, Edward B. Garon, Nashat Y. Gabrail, S. P. Lu, J. A. Neidhart, Moacyr Ribeiro de Oliveira, J. Balkissoon, Fairooz F. Kabbinavar |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Fosbretabulin Tromethamine Bevacizumab Angiogenesis business.industry non-small cell lung cancer (NSCLC) medicine.disease Carboplatin Surgery chemistry.chemical_compound chemistry Paclitaxel Internal medicine medicine Stage (cooking) business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 29:7559-7559 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2011.29.15_suppl.7559 |
| Popis: | 7559 Background: Inhibition of angiogenesis has clinical benefits in NSCLC. Depriving tumors of blood flow by adding bevacizumab (B) to other vasculature-directed agents has been hampered by toxici... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|